AKTIENANLEIHE - SANOFI/ELI LILLY & CO/ABBVIE Stock

Certificat

DE000VM8RPU1

Market Closed - Boerse Frankfurt Warrants 01:43:57 2024-05-24 pm EDT
98.28 EUR -0.62% Intraday chart for AKTIENANLEIHE - SANOFI/ELI LILLY & CO/ABBVIE
Current month-0.41%
1 month+1.05%
Date Price Change
24-05-24 98.28 -0.62%
24-05-23 98.89 -0.44%
24-05-22 99.33 -0.31%
24-05-21 99.64 +0.30%
24-05-20 99.34 +0.12%

Real-time Boerse Frankfurt Warrants

Last update May 24, 2024 at 01:43 pm EDT

More quotes

Static data

Product typeObligations Convertibles
Buy / SellCALL
Underlying SANOFI
IssuerLogo Issuer Vontobel Vontobel
WKN VM8RPU
ISINDE000VM8RPU1
Date issued 2024-02-12
Strike 77.46
Maturity 2025-02-21 (273 Days)
Parity 0.08 : 1
Emission price 100
Emission volume N/A
Settlement les deux
Currency EUR

Technical Indicators

Highest since issue 100
Lowest since issue 96.42

Company Profile

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Sector
-
More about the company

Ratings for Sanofi

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Sanofi

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
89.52 EUR
Average target price
108.2 EUR
Spread / Average Target
+20.86%
Consensus